Tucatinib Side Effects

Medically reviewed by Drugs.com. Last updated on Oct 4, 2021.

Applies to tucatinib: oral tablets.

Side effects include:

Adverse effects occurring in ≥20% of patients: Diarrhea, palmar-plantar erythrodysesthesia, nausea, fatigue, hepatotoxicity, vomiting, stomatitis, decreased appetite, abdominal pain, headache, anemia, rash.

Tucatinib increases S_cr by inhibiting tubular secretion of creatinine. Elevated S_cr concentrations are reversible following discontinuance of therapy. Use of alternative markers for renal function may be necessary if elevated S_cr concentrations persist.

For Healthcare Professionals

Applies to tucatinib: oral tablet.

Dermatologic

Very common (10% or more): Palmar-plantar erythrodysesthesia syndrome (63%), rash (e.g., rash maculopapular, rash, dermatitis acneiform, erythema, rash macular, rash papular, rash pustular, rash pruritic, rash erythematous, skin exfoliation, urticaria, dermatitis allergic, palmar erythema, plantar erythema, skin toxicity, dermatitis) (20%)^[Ref]

Gastrointestinal

Very common (10% or more): Diarrhea (81%), nausea (58%), vomiting (36%), stomatitis (e.g., stomatitis, oropharyngeal pain, oropharyngeal discomfort, mouth ulceration, oral pain, lip ulceration, glossodynia, tongue blistering, lip blister, oral dysesthesia, tongue ulceration, aphthous ulcer) (32%)^[Ref]

Hematologic

Very common (10% or more): Hemoglobin decreased (59%), decreased phosphate (57%), anemia (e.g., anemia, hemoglobin decreased, normocytic anemia) (21%)^[Ref]

Hepatic

Very common (10% or more): Bilirubin increased (47%), ALT increased (46%), AST increased (43%), hepatotoxicity (e.g., hyperbilirubinemia, blood bilirubin increased, bilirubin conjugated increased, alanine aminotransferase increased, transaminases increased, hepatotoxicity, aspartate aminotransferase increased, liver function test increased, liver injury, hepatocellular injury) (42%)^[Ref]

Metabolic

Very common (10% or more): Anorexia (25%), weight loss (13%), magnesium decreased (40%), potassium decreased (36%), alkaline phosphate increased (26%)^[Ref]

Musculoskeletal

Very common (10% or more): Arthralgia (15%)^[Ref]

Renal

Very common (10% or more): Creatinine increased (33%)^[Ref]

Respiratory

Very common (10% or more): Epistaxis

Frequently asked questions

• How effective is tucatinib (Tukysa) for breast cancer?
• What’s the difference between tucatinib and neratinib?
• What's the mechanism of action for tucatinib?

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.

Medical Disclaimer